Toxicity study in naïve mice

Stammdaten

Auftraggeber

BiconY Therapeutics GmbH, Leipzig

Veröffentlicht

07.10.2025

Frist (Submission)

12.11.2025

Notice-Typ

Ausschreibung

Verfahrensart

Offenes Verfahren

CPV-Code

73000000 — Forschung und Entwicklung

Branche

Gesundheitswesen & Medizintechnik

Rechtsgrundlage

EU-Oberschwelle

Beschreibung

The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to cre-ate new disruptive innovations from Germany. That means products, services and sys-tems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination con-sists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly im-prove the specificity, sus-tainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of concept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the IND application at Paul Ehrlich Institute (Germany) we have to show safety of our molecules in animal models. Following extensive discussions and thorough analyses, the PEI has granted approval for a comprehensive toxicological study of our lead candidate in mice. Therefore, we are looking for a service provider to support us regarding pharmaco-toxicological studies

Vertragslaufzeit

Beginn

01.12.2025

Ende

29.05.2026

Verlängerungsoption

bis zu 2× verlängerbar

Verfahrens-Bedingungen

Bindefrist

6 Wochen

Bürgschaft

erforderlich

Verfahrensverlauf — alle 2 Veröffentlichungen

• Ausschreibung · Frist: 12.11.2025
• Vergabeergebnis

Zuständige Vergabekammer (laut Bekanntmachung)

Vergabekammer des Budnes, Bonn

Angabe aus der TED-Bekanntmachung. Im Streitfall ist die tatsächlich zuständige Vergabekammer nach §§ 155 ff. GWB maßgeblich, nicht zwingend die hier genannte.